Collaboration to explore the immunoregulation of NK and T cells within the tumor microenvironment (TME) by CAPTN-3, with the ...

Purple Biotech Ltd. (NASDAQ/TASE ... The Company is advancing CAPTN-3, a preclinical platform of conditionally-activated tri-specific antibody that engages both T cells and NK cells to induce ...

About Purple Biotech Purple Biotech Ltd. (NASDAQ/TASE ... a preclinical platform of conditionally-activated tri-specific antibody that engages both T cells and NK cells to induce a strong ...

Purple Biotech (PPBT) announced that it has entered into a Research Collaboration Agreement with the Icahn School of Medicine at Mount Sinai in ...

Purple Biotech Ltd. (NASDAQ/TASE: PPBT ... The Company is advancing CAPTN-3, a preclinical platform of conditionally-activated tri-specific antibody that engages both T cells and NK cells to induce a ...

Algiax Pharmaceuticals’ non-opioid candidate has achieved “clinically meaningful” pain reduction in a mid-stage trial of ...

KEY TAKEAWAYS: 70% of Sponsors miss their milestones by an average of eight months, suggesting the clinical trial recruitment model is broken, but there is an optimized method being ...